Cancer afflicts approximately 15,000 children annually in the United States. In recent years, drug shortages for sterile injectable chemotherapies have occurred in the United States. This study seeks to estimate the amount of sterile chemotherapy used each year in the United States by pediatric cancer patients. This estimate will inform a cost analysis which will in turn be used to advocate for federal legislation to address chemotherapy shortages for pediatric cancer patients.
In this study, the study team is to estimate the amount of sterile chemotherapy used each year in the United States by pediatric cancer patients and the cost of purchasing sterile injectable chemotherapies in the United States.
Funding Source:
Participating PEDSnet Sites:
- Cincinnati Children’s Hospital Medical Center
- Children’s Hospital of Philadelphia
- Nationwide Children’s Hospital
- Seattle Children’s Hospital
- Nemours Children’s Health
Study Investigator:
Clinical Outcomes by Language of Care in Pediatric Oncology
Although language disparities in outcomes are well documented in general pediatrics and adult oncology, little is known in pediatric oncology. Patient or family language is not included in many multi- institutional databases and patient registries, limiting studies of language-based inequities…
Extreme weather impacts on children’s acute and chronic health outcomes; a multisite study with evaluation of vulnerabilities
The “Extreme Weather and Pediatric Health Outcomes” study investigates the impact of climate change-related extreme weather events, such as extreme heat and heavy rainfall, on children’s health across the United States. This innovative research aims to address critical knowledge gaps…
Characterization of Babies Born with Hemolytic Disease of the Fetus/Newborn (HDFN)
Hemolytic disease of the fetus and newborn (HDFN) otherwise known as erythroblastosis fetalis, is a disease in which fetal and neonatal erythrocytes are destroyed by maternal IgG alloantibodies. Before the first RhD immunoprophylaxis was introduced as a treatment in 1968,…